Part 2: Who to test

Share :
Published: 23 Jul 2021
Views: 3494
PARP inhibition in the treatment of prostate cancer

This series of animations investigates the use of PARP inhibitors for prostate cancer treatment and has been developed by Prof Phillip Cornford in association with ecancer.

Around 20-25% of patients with advanced prostate cancer harbour HRR defects which sensitise them to PARP inhibitors, but testing is necessary to identify these patients.

This video covers the potential implications of testing for patients and their families, current guidelines on what type of testing to use for which patients, and ongoing research into the screening of populations that are at a higher risk of developing prostate cancer.

To learn about when to test for prostate cancer click here.

To learn about how to test for prostate cancer click here.

To learn about metastatic prostate cancer and HRR defects click here.

To learn about BRCA 1-2 mutations and prostate cancer click here.

To watch an expert panel discussion on the role of testing in prostate cancer treatment click here.

To watch a discussion on the latest on PARPi and other treatments for mCRPC click here here.

This programme has been supported by an unrestricted educational grant from AstraZeneca.